Transforming Cancer Monitoring

At Oncobit, we aim to improve patient outcomes with high-precision and cutting-edge cancer monitoring solutions.

Our Mission

Enabling personalized cancer care

We use state-of-the-art technologies to develop cancer-specific monitoring tests and provide physicians with optimal therapy-decision support. Based on a simple blood sample, we offer innovative and robust solutions to closely, precisely and reliably monitor cancer and treatment response. This ensures that patients receive the best possible medical care at optimal cost efficiency.

Learn more about Oncobit

Our Solutions

Specific and sensitive tools for an optimal cancer therapy management

Our solutions provide clinicians with advanced molecular insights for precise cancer monitoring and therapy optimization.

Oncobit™ PM is a data-driven cancer monitoring platform for the sensitive and quantitative detection of specific cancer markers in circulating tumor-derived DNA (ctDNA) from the blood. It consists of cancer specific reagents and a cloud-based analysis software for automatic data interpretation and reporting. This ensures that clinicians receive an unbiased and clear report in a timely manner.

Learn more about our solutions

Our Journey

Loading…

November 2024

Oncobit closes 1.5M Pre-Series A Financing Round

We are thrilled to announce that we closed a 1.5M CHF Pre-Series A Financing round. A huge thank you to our existing and new investors for supporting our vision of enabling personalized cancer care. The investment will enable us to continue to grow and strengthen our position in the cancer monitoring market.

June 2024

Oncobit announces changes to the Board of Directors

Oncobit, a pioneer in precision cancer monitoring solutions, is pleased to announce changes to its Board of Directors. With the achievement of CE marking for our products and first revenues in Europe, the company focus shifts from product validation to clinical and commercial expansion. Following this shift the changes to the board composition, pave the way for the company’s future success. The whole Oncobit team extends heartfelt gratitude to Dr. Tomas Hruz for his invaluable contributions in the areas of bioinformatic analyses and intellectual property and warmly welcomes Prof. Mitch Levesque and Bram Goorden, MBA as new members.

June 2024

Oncobit Receives European Regulatory Approval (IVDR Certification) for Melanoma ctDNA Monitoring Tests

We are pleased to announce that we received the In Vitro Diagnostic Regulation (IVDR) certification for our Oncobit PM melanoma test suite, which allows us to CE-mark these tests and to offer them for clinical use. Oncobit PM is designed to detect specific cancer markers in the tumor-derived fraction of circulating cell-free DNA (ctDNA) isolated from the blood of melanoma patients. Oncobit PM tests detect specific cancer hot spot mutations in the genes BRAF, NRAS, GNAQ, GNA11, and SF3B1, critical for cutaneous and uveal melanoma.

Oncobit’s tests provide critical decision support in the treatment and monitoring of advanced melanoma patients.

Prof. Dr. med. Reinhard Dummer, Department of Dermatology USZ, Head of the Skin tumor center, Expert for the Comprehensive Cancer Center Zürich